• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American Journal of Physiology >Rho-kinase: important new therapeutic target in cardiovascular diseases.
【24h】

Rho-kinase: important new therapeutic target in cardiovascular diseases.

机译：Rho激酶：心血管疾病的重要新治疗靶点。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Rho-kinase (ROCKs) belongs to the family of serine/threonine kinases and is an important downstream effector of the small GTP-binding protein RhoA. There are two isoforms of Rho-kinase, ROCK1 and ROCK2, and they have different functions with ROCK1 for circulating inflammatory cells and ROCK2 for vascular smooth muscle cells. It has been demonstrated that the RhoA/Rho-kinase pathway plays an important role in various fundamental cellular functions, including contraction, motility, proliferation, and apoptosis, leading to the development of cardiovascular disease. The important role of Rho-kinase in vivo has been demonstrated in the pathogenesis of vasospasm, arteriosclerosis, ischemia-reperfusion injury, hypertension, pulmonary hypertension, stroke, and heart failure. Furthermore, the beneficial effects of fasudil, a selective Rho-kinase inhibitor, have been demonstrated for the treatment of several cardiovascular diseases in humans. Thus the Rho-kinase pathway is an important new therapeutic target in cardiovascular medicine.
机译：Rho激酶（ROCKs）属于丝氨酸/苏氨酸激酶家族，是小GTP结合蛋白RhoA的重要下游效应子。 Rho激酶有两种同工型，ROCK1和ROCK2，它们与ROCK1用于循环炎症细胞和ROCK2用于血管平滑肌细胞具有不同的功能。已经证明，RhoA / Rho激酶途径在各种基本细胞功能中起重要作用，包括收缩，运动，增殖和凋亡，从而导致心血管疾病的发展。 Rho激酶在体内的重要作用已在血管痉挛，动脉硬化，缺血再灌注损伤，高血压，肺动脉高压，中风和心力衰竭的发病机理中得到证明。此外，已经证明法舒地尔（一种选择性的Rho激酶抑制剂）的有益作用可治疗人类的几种心血管疾病。因此，Rho激酶途径是心血管医学中重要的新治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号